Last reviewed · How we verify
Ultratrace Iobenguane I131
At a glance
| Generic name | Ultratrace Iobenguane I131 |
|---|---|
| Also known as | Azedra, MIBG |
| Sponsor | Molecular Insight Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma (PHASE2)
- Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
- N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma (PHASE2)
- Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma (PHASE1, PHASE2)
- Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma (PHASE2)
- ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultratrace Iobenguane I131 CI brief — competitive landscape report
- Ultratrace Iobenguane I131 updates RSS · CI watch RSS
- Molecular Insight Pharmaceuticals, Inc. portfolio CI